Page 138 - 《中国药房》2026年1期

[ 9 ] LASRADO N，COLLIER A Y，MILLER J，et al. Waning plications[J]. Genes Cancer，2015，6（3/4）：84-105.
immunity and IgG4 responses following bivalent mRNA [22] JEON Y，JO U，HONG J，et al. Trophoblast cell-surface
boosting[J]. Sci Adv，2024，10（8）：eadj9945. antigen 2 （TROP2） expression in triple-negative breast
[10] SINGH S B. Discovery and development of dolastatin 10- cancer[J]. BMC Cancer，2022，22（1）：1014.
derived antibody drug conjugate anticancer drugs[J]. J Nat [23] SANTI D V，CABEL L，BIDARD F C. Does sacituzumab-
Prod，2022，85（3）：666-687. govitecan act as a conventional antibody drug conjugate
[11] LI F，EMMERTON K K，JONAS M，et al. Intracellular re‐ （ADC），a prodrug of SN-38 or both [J]. Ann Transl Med，
leased payload influences potency and bystander-killing 2021，9（14）：1113.
effects of antibody-drug conjugates in preclinical models [24] BARDIA A，MAYER I A，VAHDAT L T，et al. Sacitu‐
[J]. Cancer Res，2016，76（9）：2710-2719. zumab govitecan-hziy in refractory metastatic triple-
[12] KALINOVSKY D V， KHOLODENKO I V， negative breast cancer[J]. N Engl J Med，2019，380（8）：
SVIRSHCHEVSKAYA E V，et al. Targeting GD2-positive 741-751.
tumor cells by pegylated scFv fragment-drug conjugates [25] BARDIA A，HURVITZ S A，TOLANEY S M，et al. Saci‐
carrying maytansinoids DM1 and DM4[J]. Curr Issues tuzumab govitecan in metastatic triple-negative breast can‐
Mol Biol，2023，45（10）：8112-8125. cer[J]. N Engl J Med，2021，384（16）：1529-1541.
[13] FU Z W，LI S J，HAN S F，et al. Antibody drug conjugate： [26] OKAJIMA D，YASUDA S，MAEJIMA T，et al. Datopota‐
the “biological missile” for targeted cancer therapy[J]. mab deruxtecan，a novel TROP2-directed antibody-drug
Signal Transduct Target Ther，2022，7：93. conjugate，demonstrates potent antitumor activity by effi‐
[14] JABBOUR E，PAUL S，KANTARJIAN H. The clinical de‐ cient drug delivery to tumor cells[J]. Mol Cancer Ther，
velopment of antibody-drug conjugates：lessons from leu‐ 2021，20（12）：2329-2340.
kaemia[J]. Nat Rev Clin Oncol，2021，18（7）：418-433. [27] SHIMIZU T，SANDS J，YOH K，et al. First-in-human，
[15] CRISCITIELLO C，CORTI C，DE LAURENTIIS M， phase Ⅰ dose-escalation and dose-expansion study of tro‐
et al. Tucatinib’s journey from clinical development to phoblast cell-surface antigen 2-directed antibody-drug
clinical practice：new horizons for HER-2-positive meta‐ conjugate datopotamab deruxtecan in non-small-cell lung
static disease and promising prospects for brain metastatic cancer：TROPION-PanTumor01[J]. J Clin Oncol，2023，41
spread[J]. Cancer Treat Rev，2023，120：102618. （29）：4678-4687.
[16] TANG Y B，TANG F，YANG Y，et al. Real-time analysis [28] SCHMID P，WYSOCKI P J，MA C X，et al. 379MO：dato‐
on drug-antibody ratio of antibody-drug conjugates for potamab deruxtecan （Dato-DXd） + durvalumab （D） as
synthesis，process optimization，and quality control[J]. Sci first-line （1L） treatment for unresectable locally ad‐
Rep，2017，7（1）：7763. vanced/metastatic triple-negative breast cancer （a/mT‐
[17] XU Z Y，GUO D D，JIANG Z L，et al. Novel HER-2-tar‐ NBC）：updated results from BEGONIA，a phase Ⅰb/Ⅱ
geting antibody-drug conjugates of trastuzumab beyond T- study[J]. Ann Oncol，2023，34：S337.
DM1 in breast cancer：trastuzumab deruxtecan（DS- [29] CHENG Y Z，YUAN X X，TIAN Q，et al. Preclinical pro‐
8201a） and （vic-） trastuzumab duocarmazine （SYD985） files of SKB264，a novel anti-TROP2 antibody conjugated
[J]. Eur J Med Chem，2019，183：111682. to topoisomerase inhibitor，demonstrated promising antitu‐
[18] OGITANI Y，HAGIHARA K，OITATE M，et al. By‐ mor efficacy compared to IMMU-132[J]. Front Oncol，
stander killing effect of DS-8201a，a novel anti-human epi‐ 2022，12：951589.
dermal growth factor receptor 2 antibody-drug conjugate， [30] XU B H，YIN Y M，FAN Y，et al. Sacituzumab tirumote‐
in tumors with human epidermal growth factor receptor 2 can （SKB264/MK-2870） in patients （PTS） with pre-
heterogeneity[J]. Cancer Sci，2016，107（7）：1039-1046. viously treated locally recurrent or metastatic triple-
[19] DIÉRAS V，DELUCHE E，LUSQUE A，et al. Abstract negative breast cancer （TNBC）：results from the phase Ⅲ
PD8-02：trastuzumab deruxtecan （T-DXd） for advanced OptiTROP-Breast01 study[J]. J Clin Oncol，2024，42
breast cancer patients （ABC），regardless HER-2 status：a （Suppl. 16）：104.
phase Ⅱ study with biomarkers analysis （DAISY）[J]. [31] TAYLOR K M，MORGAN H E，JOHNSON A，et al.
Cancer Res，2022，82（Suppl. 4）：PD8-2-PD8-02. Structure-function analysis of LIV-1，the breast cancer-
[20] MODI S N，JACOT W，YAMASHITA T，et al. Trastu‐ associated protein that belongs to a new subfamily of zinc
zumab deruxtecan in previously treated HER-2-low ad‐ transporters[J]. Biochem J，2003，375（Pt 1）：51-59.
vanced breast cancer[J]. N Engl J Med，2022，387（1）： [32] SUSSMAN D，SMITH L M，ANDERSON M E，et al.
9-20. SGN-LIV1A：a novel antibody-drug conjugate targeting
[21] SHVARTSUR A，BONAVIDA B. TROP2 and its overex‐ LIV-1 for the treatment of metastatic breast cancer[J]. Mol
pression in cancers：regulation and clinical/therapeutic im‐ Cancer Ther，2014，13（12）：2991-3000.

· 128 · China Pharmacy 2026 Vol. 37 No. 1 中国药房 2026年第37卷第1期